Lupin Limited announced the strategic spin-out of two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), through its wholly owned subsidiary Lupin Inc., into Kaveri Therapeutics Inc. This move aims to advance the programs through global clinical trials for solid tumors. Under the agreement, Lupin Inc. acquired an 82.2% equity stake in Kaveri, consisting of 332,000 Common Shares, and provided seed funding in exchange for exclusive rights to the two assets. The transaction, valued at USD 1.6 million, was completed on July 20, 2026.

Kaveri Therapeutics is a clinical-stage oncology company incorporated in Delaware, U.S.A., on May 20, 2026. The entity reported nil turnover and net worth at the time of filing. Kaveri will operate independently under the leadership of Chief Executive Officer Kristi Jones and Chief Medical Officer Dr. Robert Pierce. The company intends to raise additional capital to fund its clinical development efforts, focusing on biomarker-driven strategies for hard-to-treat cancers including lung, pancreatic, ovarian, and CNS-related malignancies.

The oncology programs involved have demonstrated encouraging clinical progress. LNP7457 (PRMT5) and LNP8701 (SOS1) reported positive data at the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively. Vinita Gupta, Chief Executive Officer of Lupin, stated that the strength of these assets, combined with Kaveri's leadership, positions the company to accelerate the development of targeted therapies.

Key Transaction Details

The disclosure was submitted to the National Stock Exchange of India and BSE Limited under Regulation 30 of the SEBI Listing Regulations. The transaction aligns with Lupin's strategy to innovate in targeted oncology therapies by spinning out specific programs to specialized entities.

A notable block trade was recorded on the National Stock Exchange (NSE) for Lupin Ltd., with approximately 1,10,946 shares transacted at a price of Rs. 2444.40 per share. The total value of the block deal stood at Rs. 27.12 crores, reflecting significant institutional-level participation in the counter.

Block Trade Details

The following table summarizes the key parameters of the block trade executed on the NSE:

Block trades are large-volume transactions typically executed between institutional investors outside of the open market order book, often reflecting portfolio rebalancing or strategic position changes by major market participants. The execution of such a trade in Lupin underscores active institutional interest in the pharmaceutical company's stock.